The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants

Clinical Transplantation

Volumn 17, Issue 5, 2003, Pages 428-432

  Ciancio, Gaetano ^a   Mattiazzi, Adela ^a   Roth, David ^a   Kupin, Warren ^a   Miller, Joshua ^a   Burke, George W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Induction therapy; Mycophenolate mofetil; Previous transplants; Tacrolimus

Indexed keywords

COTRIMOXAZOLE; DACLIZUMAB; GANCICLOVIR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CADAVER DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; SIDE EFFECT; URINARY TRACT INFECTION; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; REOPERATION; TACROLIMUS;

EID: 0141990520     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2003.00066.x     Document Type: Article

References (29)

1. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
2. Pirsh JD, Miller J, Deierhoi MH, Vicenti F, Filo R. Comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997: 63: 977.
3. Ciancio G, Lo Monte A, Buscemi G, Miller J, Burke GW. Use of tacrolimus and mycophneolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation. Transplant Int 2000: 13: S191.
4. Ciancio G, Miller J, Burke GW. The use of intravenous tacrolimus and mycophenolate mofetil as induction and maintenance immunosuppression in simultaneous pancreas-kidney recipients with previous transplants. Clin Transplant 2001: 15: 142.
5. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161.
6. Nashan B, Light S, Hardie IR, Lin A, Johson R, for the Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by Daclizumab. Transplantation 1999: 67: 110.
7. Ciancio G, Burke GW, Suzart K et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002: 73: 1100.
8. Vincenti F, for the Tacrolimus Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc 2001: 33: 1019.
9. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaver transplantation. Transplantation 1996: 61: 1029.
10. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999: 68: 391.
11. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.
12. Vicenti F, Lantz M, Birnbaum J et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997: 63: 33.
13. Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vicenti F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transplant Int 2000: 13: 151.
14. Stratta RJ, Oh CS, Sollinger HW, Pirsch JD, Kalayoglu M, Belzer FO. Kidney retransplatation in the cyclosporine era. Transplantation 1988: 45: 40.
15. Cardella CJ, Blake P, Cattran D, Cole E. Prophylactic OKT3 in renal retransplantation. Transplant Proc 1989: 21: 3373.
16. Peraldi MN, Akposso K, Haymann JP et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996: 62: 1670.
17. Karakayali H, Moray G, Demiraǧ A et al. Long-term renal retransplantation and graft survival rates at our center. Transplant Proc 1998: 30: 762.
18. Hiesse C, Neyrat N, Busson M et al. High rate of success in kidney cadaveric retransplantation with optimal matching and potent immunosuppression. Transplant Proc 1990: 22: 1909.
19. Deeb GM, Bolling SF, Steile CN, Dawae JE, McKay AI, Richardson AM. A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection. Transplantation 1991: 51: 180.
20. Oh CS, Stratta RJ, Fox BC, Sollinger HW, Belzer FO, Maki DG. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988: 45: 68.
21. Bock HA, Gallati H, Zurcher RM et al. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation 1995: 59: 830.
22. Bailey TC, Powderly WG, Storch GA et al. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis 1993: 21: 196.
23. Ciancio G, Siquijor AP, Burke GW et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 1997: 11: 243.
24. Brayman KL, Stephanian E, Matas AJ et al. Analysis of infectious complications occurring after solid-organ transplantation. Arch Surg 1992: 127: 38.
25. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990: 323: 1723.
26. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients: clinical experience and risk factor analysis in a single center. Transplantation 1993: 56: 88.
27. First MR, Schroeder TJ, Hurtubise PE et al. Successful retreatment with OKT3. Transplantation 1989: 47: 88.
28. Norman DJ, Shield CF, Henell KR et al. Effectiveness of a second course of OKT3 monoclonal anti-T-cell antibody for treatment of renal allograft rejection. Transplantation 1988: 46: 523.
29. Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997: 5: 225.